2020 Ashish Kulkarni, Brigham and Women's Hospital PKCalpha as a node to overcome intrinsic MEK inhibitor resistance in melanoma: Aims to validate PKCalpha as a highly promising avenue for clinical translation, particularly for non-BRAF-mutant melanoma University of Texas M.D. Anderson Cancer Center-MR